Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza on näidustatud inimese immuunpuudulikkuse viiruse 1. tüüpi (hiv-1) nakkuse raviks täiskasvanutel ja noorukitel (12-aastased ja vanemad kehakaaluga vähemalt 40 kg). genotypic testing should guide the use of symtuza.

Eesti - eesti - Ravimiamet

accord healthcare b.v. - ritonaviir - õhukese polümeerikattega tablett - 100mg 30tk; 100mg 120tk; 100mg 90tk

Eesti - eesti - Ravimiamet

pro.med.cs praha a.s. - itrakonasool - kõvakapsel - 100mg 18tk; 100mg 28tk; 100mg 14tk; 100mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

alfasigma s.p.a. - metüültioniiniumkloriid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - viirusevastased ravimid süsteemseks kasutamiseks - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastilised ained - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.